Tolchard S, Burns P A, Nutt D J, Fitzjohn S M
Department of Anaesthesia, Frenchay Hospital, North Bristol NHS Trust, Frenchay, Bristol, UK.
Br J Anaesth. 2009 Oct;103(4):554-60. doi: 10.1093/bja/aep199. Epub 2009 Jul 23.
alpha(2)-Adrenoceptor agonists are currently used as primary sedative agents in high dependency patients who are at high risk of sepsis. Clinical surveillance of such patients relies in part on their ability to mount appropriate responses to infection, in particular thermal responses. Thermoregulatory responses to infection are well studied in the rat and in this species, and humans, infection can induce febrile, hypothermic, or mixed hypothermic and febrile responses. The involvement of noradrenergic systems in thermal responses to infection prompted the hypothesis that ligands that act on adrenoceptors may interfere with the normal thermal responses to infection.
In this study on rats, the effect of infusion of the selective alpha(2)-agonist, mivazerol, on hypothermic and plasma corticosterone responses induced by bacterial lipopolysaccharide (LPS) was investigated.
Clinically effective doses of mivazerol (4.8 and 10 microg kg(-1) h(-1)) had no effect on body temperature alone. However, mivazerol significantly inhibited the typical thermoregulatory response to bacterial LPS in a dose-dependent manner. This effect was mimicked by the selective alpha(2)-agonist, UK14304-18 (6 microg kg(-1) h(-1)), and antagonized by the alpha(2)-antagonist, RX811059A (7 microg kg(-1) h(-1)). The alpha(2)-ligands had no effect on basal or LPS-induced corticosterone levels.
These data suggest that early thermoregulatory responses to infection can be selectively antagonized by ligands that activate alpha(2)-adrenoreceptors. High dependency patients receiving alpha(2)-adrenoceptor agonists may not be capable of mounting a normal thermal response to infecting organisms and clinical monitoring using core temperature to detect infection may therefore be unreliable in these vulnerable patients.
α₂肾上腺素能激动剂目前被用作脓毒症高风险的高依赖患者的主要镇静剂。对此类患者的临床监测部分依赖于他们对感染产生适当反应的能力,尤其是体温反应。在大鼠以及人类中,对感染的体温调节反应已得到充分研究,感染可诱发发热、体温过低或体温过低与发热混合的反应。去甲肾上腺素能系统参与对感染的体温反应,这促使人们提出这样的假设,即作用于肾上腺素能受体的配体可能会干扰对感染的正常体温反应。
在这项对大鼠的研究中,研究了输注选择性α₂激动剂米伐折醇对细菌脂多糖(LPS)诱导的体温过低和血浆皮质酮反应的影响。
临床有效剂量的米伐折醇(4.8和10微克·千克⁻¹·小时⁻¹)单独对体温没有影响。然而,米伐折醇以剂量依赖的方式显著抑制了对细菌LPS的典型体温调节反应。选择性α₂激动剂UK14304 - 18(6微克·千克⁻¹·小时⁻¹)模拟了这种效应,而α₂拮抗剂RX811059A(7微克·千克⁻¹·小时⁻¹)则拮抗了这种效应。α₂配体对基础或LPS诱导的皮质酮水平没有影响。
这些数据表明,激活α₂肾上腺素能受体的配体可选择性拮抗对感染的早期体温调节反应。接受α₂肾上腺素能激动剂的高依赖患者可能无法对感染生物体产生正常的体温反应,因此在这些脆弱患者中,使用核心体温检测感染的临床监测可能不可靠。